ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cyclobenzaprine

Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.

Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.

Drug pageCyclobenzaprine: every studyMany companies study it; this page follows only the 32 they lead. All 42 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 12, 201332 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonix Pharmaceuticalsits history only262 open or runningphase 3since Jul 12, 2013Dec 7, 2011Feb 2028phase 2 · NCT07621237
Eurofarma Laboratoriosits history only10 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Johnson & Johnsonits history only10 open or runningphase 4since Oct 28, 2005Oct 28, 2005none ahead
Neurana Pharmaceuticalsits history only10 open or runningphase 1since Nov 14, 2017Nov 14, 2017none ahead
Novartis10 open or runningphase 1since Jun 2, 2009Jun 2, 2009none ahead
Sun Pharmaceutical Industriesits history only10 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
Takedaits history only10 open or runningphase 3since Jun 23, 2016Jun 23, 2016none ahead

Also a collaborator on its studies: Altasciences, Premier Research Group and Cognitive Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 2, 2009First study: phase 1 study in DepressionFirst studyNCT00913419 · 30 enrolled

TargetBeta

HTR2A →HTR2C →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
TrazodoneruleAngelini Pharmaphase 314

Studies

The one study Novartis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00913419Depression1CompletedDec 198830

How it is read

Names in the registry

  • “TNX-102 SL”, 13 entries
  • “TNX-102 SL 5.6 mg”, 2 entries
  • “Treatment A”, 2 entries
  • “Treatment B”, 2 entries
  • “TNX-102 SL Tablet”, 1 entry

Codes read as this program: TNX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.